Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CRHR1 | P34998 | 9/20 | 0.61 |
| ▸ | ITGB2 | P05107 | 2/20 | 0.43 |
| ▸ | ICAM1 | P05362 | 2/20 | 0.43 |
| ▸ | ITGAL | P20701 | 2/20 | 0.43 |
| ▸ | MAPT | P10636 | 3/20 | 0.40 |
| ▸ | TBXA2R | P21731 | 1/20 | 0.40 |
| ▸ | PTGFR | P43088 | 1/20 | 0.40 |
| ▸ | PTGER3 | P43115 | 1/20 | 0.40 |
| ▸ | PTGER2 | P43116 | 1/20 | 0.40 |
| ▸ | PTGIR | P43119 | 1/20 | 0.40 |
| ▸ | PTGDR | Q13258 | 1/20 | 0.40 |
| ▸ | PLA2G1B | P04054 | 1/20 | 0.40 |
| ▸ | ATG4B | Q9Y4P1 | 1/20 | 0.40 |
| ▸ | IDH1 | O75874 | 2/20 | 0.38 |
| ▸ | RAB9A | P51151 | 2/20 | 0.37 |
| ▸ | NPC1 | O15118 | 1/20 | 0.37 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.37 |
| ▸ | MAOB | P27338 | 1/20 | 0.37 |
| ▸ | LMNA | P02545 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3672054 | 1.00 | CRHR1 (0.61) | CRHR1ITGB2ICAM1ITGALMAPT | |
| SCHEMBL3756232 | 0.88 | CRHR1 (0.63) | CRHR1ITGB2ICAM1ITGALMAPT | |
| SCHEMBL3756236 | 0.88 | CRHR1 (0.63) | CRHR1ITGB2ICAM1ITGALMAPT | |
| SCHEMBL13774764 | 0.86 | CRHR1 (0.60) | CRHR1MAPTRAB9ANPC1SMN1; SMN2 | |
| SCHEMBL13058114 | 0.86 | CRHR1 (0.62) | CRHR1MAPTRAB9ANPC1SMN1; SMN2 | |
| SCHEMBL3664462 | 0.86 | CRHR1 (0.68) | CRHR1MAOB | |
| SCHEMBL3667990 | 0.84 | CRHR1 (0.63) | CRHR1SMN1; SMN2ALDH1A1MAOB | |
| SCHEMBL3748617 | 0.81 | CRHR1 (0.62) | CRHR1ALDH1A1MAOB | |
| SCHEMBL3666067 | 0.80 | CRHR1 (0.69) | CRHR1ALDH1A1MAOBLMNA | |
| SCHEMBL3668983 | 0.79 | CRHR1 (0.70) | CRHR1MAOB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8901141-B2 | Tricyclic compounds having corticotropin-releasing factor antagonistic activity and pharmaceutical compositions containing them | TAKEDA PHARMACEUTICAL COMPANY, LIMITED (JP) | 2014-12-02 | — | — | US | disclosed |
| EP-2240485-B1 | TRICYCLIC COMPOUNDS HAVING CORTICOTROPIN-RELEASING FACTOR ANTAGONISTIC ACTIVITY AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | TAKEDA PHARMACEUTICAL (JP) | 2014-10-15 | — | — | EP | disclosed |
| US-8785460-B2 | Tricyclic compounds and use thereof | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2014-07-22 | — | — | US | disclosed |
| US-20100298287-A1 | TRICYCLIC COMPOUNDS HAVING CORTICOTROPIN-RELEASING FACTOR ANTAGONISTIC ACTIVITY AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2010-11-25 | — | — | US | disclosed |
| EP-2240485-A1 | TRICYCLIC COMPOUNDS HAVING CORTICOTROPIN-RELEASING FACTOR ANTAGONISTIC ACTIVITY AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | Takeda Pharmaceutical Company Limited (JP) | 2010-10-20 | — | — | EP | disclosed |
| WO-2009093747-A1 | TRICYCLIC COMPOUNDS HAVING CORTICOTROPIN-RELEASING FACTOR ANTAGONISTIC ACTIVITY AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2009-07-30 | — | — | WO | disclosed |
| US-20090186879-A1 | TRICYCLIC COMPOUNDS AND USE THEREOF | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2009-07-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090186879-A1 | TRICYCLIC COMPOUNDS AND USE THEREOF | CRHR1, CRHR2, HCRTR1 | CRHR1 1/4885ITGB2 4271/4885ICAM1 4880/4885 |
| US-20100298287-A1 | TRICYCLIC COMPOUNDS HAVING CORTICOTROPIN-RELEASING FACTOR ANTAGONISTIC ACTIVITY AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | CRH, CRHR1, CRHR2 | CRHR1 2/4885ITGB2 4576/4885ICAM1 4880/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.